130% Stock Return, 130% Profit Growth: What’s Driving NGL Fine Chem Ltd’s Multibagger Rerating?

Multibagger Status and Benchmark Comparison

NGL Fine Chem Ltd has delivered a remarkable 130.3% return over the past year, vastly outperforming the Sensex, which declined by 6.63% in the same period. This outperformance extends beyond the one-year horizon: the stock has returned 95.62% over three years and 65.32% over five years, compared to Sensex gains of 23.33% and 50.69% respectively. Over a decade, the stock’s return of 1,031.71% dwarfs the Sensex’s 194.83%, marking NGL Fine Chem Ltd as a genuine long-term compounder.

Recent Quarterly Results and Growth Drivers

The company’s latest quarterly results reinforce the fundamental growth story. Net sales reached a record ₹149.23 crore, while profit before tax (PBT) surged 656.16% to ₹15.35 crore. Net profit growth was even more striking, up 2,398.15% to ₹13.49 crore. This marks the second consecutive quarter of positive results, signalling operational momentum. The surge in quarterly profits significantly outpaces the annualised profit growth rate, suggesting an acceleration in earnings that may justify the stock’s rerating — does this quarterly acceleration indicate a sustainable earnings trajectory?

Returns Versus Fundamentals: PEG Ratio and Valuation Expansion

The close alignment of stock returns and profit growth is unusual for a multibagger. The price-to-earnings (P/E) ratio stands at 35.76, slightly above the industry average of 34.53, indicating a modest premium. The PEG ratio, calculated as P/E divided by earnings growth, is approximately 0.3, which is low and suggests the stock is not excessively priced relative to its growth. This contrasts with many multibaggers where P/E expansion drives most of the return. Here, the market appears to be rewarding genuine earnings expansion rather than speculative rerating — is this alignment between earnings and price growth a sign of a fundamentally supported rally?

Long-Term Track Record: Consistent Compounder or Recent Spike?

While the one-year return of 130.3% is eye-catching, the longer-term performance confirms that NGL Fine Chem Ltd is not a one-year wonder. The 10-year return of over 1,000% places it among the top performers in the Pharmaceuticals & Biotechnology sector. However, the five-year return of 65.32% is more modest, indicating that the recent surge has accelerated the pace of gains. This suggests a company that has steadily compounded value but has recently entered a phase of faster growth.

Valuation Context: P/E, ROCE and Capital Efficiency

The company’s return on capital employed (ROCE) is 7.2%, which is moderate for a stock trading at a P/E of 35.76. This indicates that while the business generates reasonable returns on capital, the market is pricing in expectations of improved capital efficiency or sustained growth. The enterprise value to capital employed ratio of 5.3 further highlights the premium valuation. Despite this, the company’s low debt-to-equity ratio of 0.02 times reflects a conservative capital structure, reducing financial risk. The valuation premium is thus supported by strong earnings growth but raises questions about whether the market is pricing in perfection — is the current valuation justified by the company’s operational metrics?

Performance Versus Sensex: Market Leadership in a Challenging Environment

Over multiple timeframes, NGL Fine Chem Ltd has consistently outperformed the Sensex. The stock’s 3-month return of 30.02% contrasts with the Sensex’s decline of 7.26%, while the year-to-date return of 105.82% far exceeds the Sensex’s negative 10.46%. This leadership in a challenging market environment underscores the company’s resilience and growth potential. However, the operating profit has declined at an annual rate of 5.32% over the last five years, which tempers the narrative of unbroken growth and invites scrutiny of the sustainability of recent gains.

Conclusion: Earnings Growth Drives Returns, But Valuation Warrants Attention

The 130.3% return of NGL Fine Chem Ltd over the past year is closely matched by a 130.5% increase in net profit, a rare alignment that indicates the rally is fundamentally supported rather than purely driven by multiple expansion. The company’s strong quarterly acceleration and record revenues add further credibility to this growth narrative. However, the moderate ROCE and premium valuation metrics suggest the market is pricing in continued above-average performance. The stock’s long-term track record confirms it as a compounder, but the recent surge raises the question of sustainability — is the multibagger run fully justified by the fundamentals, or has the valuation stretched ahead of the business?

Only Rs. 20,999 - Get MojoOne + Stock of the Week for 3 Years Get 71% Off →